Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00182312




Registration number
NCT00182312
Ethics application status
Date submitted
13/09/2005
Date registered
16/09/2005
Date last updated
22/03/2018

Titles & IDs
Public title
Caffeine for Apnea of Prematurity (CAP)
Scientific title
Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants
Secondary ID [1] 0 0
ISRCTN44364365
Secondary ID [2] 0 0
CTMG-1999-CAP
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Apnea of Prematurity 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Sleep apnoea
Reproductive Health and Childbirth 0 0 0 0
Complications of newborn
Reproductive Health and Childbirth 0 0 0 0
Childbirth and postnatal care
Reproductive Health and Childbirth 0 0 0 0
Fetal medicine and complications of pregnancy

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Caffeine citrate injection

Treatment: Drugs: Caffeine citrate injection
Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.

Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.

Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
combined rate of mortality and neurodevelopmental disability in survivors at a corrected age of 18 months.
Timepoint [1] 0 0
corrected age of 18 months
Secondary outcome [1] 0 0
bronchopulmonary dysplasia
Timepoint [1] 0 0
discharge home
Secondary outcome [2] 0 0
necrotizing enterocolitis
Timepoint [2] 0 0
discharge home
Secondary outcome [3] 0 0
brain injury: intra- and periventricular hemorrhage, periventricular leucomalacia and/or ventriculomegaly
Timepoint [3] 0 0
discharge home
Secondary outcome [4] 0 0
retinopathy of prematurity
Timepoint [4] 0 0
discharge home
Secondary outcome [5] 0 0
growth failure
Timepoint [5] 0 0
corrected age of 18 months
Secondary outcome [6] 0 0
functional status at 5 years and at 11-12 years
Timepoint [6] 0 0
corrected age of 5 years and chronological age of 11-12 years

Eligibility
Key inclusion criteria
* birthweight 500 to 1250 grams
* postnatal age day 1 to day 10
* infant considered a candidate for methylxanthine therapy by clinical staff
Minimum age
No limit
Maximum age
10 Days
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment
* unlikely to comply with long-term follow-up
* prior treatment with a methylxanthine

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/1999
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2016
Sample size
Target
2000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,SA,VIC
Recruitment hospital [1] 0 0
Canberra Hospital - Canberra
Recruitment hospital [2] 0 0
Women's & Children's Hospital - Adelaide
Recruitment hospital [3] 0 0
Mercy Hospital for Women - Melbourne
Recruitment hospital [4] 0 0
Royal Women's Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2605 - Canberra
Recruitment postcode(s) [2] 0 0
5006 - Adelaide
Recruitment postcode(s) [3] 0 0
3002 - Melbourne
Recruitment postcode(s) [4] 0 0
3053 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New York
Country [2] 0 0
Canada
State/province [2] 0 0
Alberta
Country [3] 0 0
Canada
State/province [3] 0 0
British Columbia
Country [4] 0 0
Canada
State/province [4] 0 0
Manitoba
Country [5] 0 0
Canada
State/province [5] 0 0
New Brunswick
Country [6] 0 0
Canada
State/province [6] 0 0
Ontario
Country [7] 0 0
Canada
State/province [7] 0 0
Quebec
Country [8] 0 0
Canada
State/province [8] 0 0
Saskatchewan
Country [9] 0 0
Germany
State/province [9] 0 0
Munich
Country [10] 0 0
Germany
State/province [10] 0 0
Tuebingen
Country [11] 0 0
Israel
State/province [11] 0 0
Beer Sheva
Country [12] 0 0
Israel
State/province [12] 0 0
Kfar-Saba
Country [13] 0 0
Israel
State/province [13] 0 0
Rehovot
Country [14] 0 0
Netherlands
State/province [14] 0 0
Amsterdam
Country [15] 0 0
Netherlands
State/province [15] 0 0
Maastricht
Country [16] 0 0
Sweden
State/province [16] 0 0
Stockholm
Country [17] 0 0
Switzerland
State/province [17] 0 0
Basel
Country [18] 0 0
Switzerland
State/province [18] 0 0
Geneva
Country [19] 0 0
Switzerland
State/province [19] 0 0
Zurich
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Northern Ireland
Country [21] 0 0
United Kingdom
State/province [21] 0 0
Middlesbrough
Country [22] 0 0
United Kingdom
State/province [22] 0 0
Newcastle-upon-Tyne

Funding & Sponsors
Primary sponsor type
Other
Name
McMaster University
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
Canadian Institutes of Health Research (CIHR)
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
National Health and Medical Research Council, Australia
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Barbara K Schmidt, MD
Address 0 0
McMaster University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents


Results not provided in https://clinicaltrials.gov/study/NCT00182312